Avelumab and Merkel Cell Carcinoma: Clinical Evidence Review

From General Health Education to Targeted Clinical Inquiry

The Immunodeficiency Foundation’s archival mission has long centered on the broad dissemination of general health and science information, particularly regarding immune system function and its role in maintaining overall well-being. This legacy of accessible, foundational knowledge has served as a vital resource for understanding how the body’s defenses operate in both healthy and compromised states. Within this context, the Foundation’s historical emphasis on general health literacy provides a natural foundation for examining more specific intersections between medical interventions and biological outcomes. As the scope of clinical inquiry has evolved, the same principles of rigorous information stewardship now extend to evaluating therapeutic agents and their potential downstream effects. This progression leads logically to a focused consideration of occupational and environmental exposure scenarios. In particular, the clinical evidence surrounding Avelumab—a monoclonal antibody used in oncology—and its association with Merkel Cell Carcinoma presents a pertinent case. The transition from general health education to this targeted inquiry requires careful attention to exposure contexts, including those encountered in healthcare and research settings. By pivoting from broad immune system education to the specific question of Avelumab exposure and Merkel Cell Carcinoma risk, the Foundation’s archival approach can now accommodate a more nuanced occupational health perspective, without venturing into mechanistic speculation.

Avelumab Pharmacology and Clinical Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This section bridges the Foundation’s general health education mission with a focused review of avelumab’s role in MCC treatment, emphasizing the importance of understanding both therapeutic benefits and potential risks.

Clinical Presentation and Diagnosis of Merkel Cell Carcinoma

MCC is a rare, highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinically, MCC typically presents as a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, most commonly on the head, neck, and extremities. Diagnosis is confirmed by histopathology and immunohistochemistry, which typically shows expression of neuroendocrine markers such as cytokeratin 20 and chromogranin A. Staging involves imaging to assess for regional lymph node involvement and distant metastases.

Avelumab Pharmacology and Reported Adverse Effects

Avelumab functions by blocking PD-L1 on tumor cells and immune cells, thereby enhancing T-cell-mediated antitumor immune responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). As an immune checkpoint inhibitor, avelumab can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported irAEs include hypercalcaemia secondary to reactivation of sarcoidosis, as described in a case report of a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). In that case, hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other common irAEs associated with avelumab include fatigue, infusion-related reactions, and dermatologic, gastrointestinal, and endocrine toxicities, though specific rates for MCC patients are not detailed in the provided evidence.

Mechanistic Pathways and Risk Considerations

The relationship between avelumab and MCC is primarily therapeutic rather than causative. Avelumab is indicated for the treatment of metastatic MCC, and its mechanism of action—blocking PD-L1—is intended to enhance immune recognition and destruction of MCC cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the evidence also highlights that avelumab can be associated with immune-related adverse events, such as sarcoidosis reactivation, which may complicate the clinical course of MCC patients (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, for patients who become refractory to avelumab, alternative immune checkpoint inhibitor combinations, such as ipilimumab plus nivolumab, have shown activity, with three out of five avelumab-refractory patients responding in one study (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study reported response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic MCC, though this includes avelumab and other agents (https://pubmed.ncbi.nlm.nih.gov/36450381/). These data underscore that while avelumab is an effective treatment, resistance can develop, and subsequent therapies may be needed. From a causation perspective, the evidence does not support a direct causal link between avelumab exposure and the development of MCC. Rather, avelumab is used to treat existing MCC. However, the risk of immune-related adverse events during avelumab therapy is well-documented. The adequacy of warnings regarding these adverse events is reflected in the clinical literature, which reports cases such as hypercalcaemia due to sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). For affected patients, the timeline between avelumab exposure and documented harm can vary; in the sarcoidosis case, hypercalcaemia developed during treatment and resolved with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline to subsequent therapy and response is variable, as seen in the retrospective studies where avelumab-refractory patients were later treated with ipilimumab plus nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The risk of progression on avelumab is significant, with approximately 50% of advanced MCC patients not responding to immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/). This highlights the need for ongoing monitoring and alternative treatment strategies.

Conclusion

In summary, avelumab is an approved and effective therapy for metastatic MCC, with a mechanism of action that enhances antitumor immunity. While it does not cause MCC, it can induce immune-related adverse events that require clinical management. The evidence supports that avelumab is a treatment for MCC, not a trigger for its development. For patients who become refractory, alternative immunotherapies may offer benefit. Clinicians should be aware of the potential for irAEs and the need for close monitoring during avelumab therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is used to treat Merkel cell carcinoma (MCC) and does not cause it. The evidence supports avelumab as a therapeutic agent for metastatic MCC, not a trigger for its development (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the common side effects of avelumab in MCC patients?

Common immune-related adverse events (irAEs) include fatigue, infusion-related reactions, dermatologic, gastrointestinal, and endocrine toxicities. A case report also describes hypercalcaemia due to sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/).

What is the success rate of avelumab for metastatic MCC?

In the JAVELIN Merkel 200 trial, approximately one-third of patients with chemotherapy-refractory metastatic MCC achieved a confirmed objective response (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, about 50% of advanced MCC patients do not respond to immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.